Centaurus Financial Inc. lifted its position in McKesson Co. (NYSE:MCK – Get Rating) by 5.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 547 shares of the company's stock after buying an additional 30 shares during the period. Centaurus Financial Inc.'s holdings in McKesson were worth $178,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Aaron Wealth Advisors LLC lifted its position in McKesson by 30,460.5% during the first quarter. Aaron Wealth Advisors LLC now owns 890,838 shares of the company's stock valued at $2,910,000 after purchasing an additional 887,923 shares in the last quarter. Acadian Asset Management LLC lifted its position in McKesson by 360.8% during the first quarter. Acadian Asset Management LLC now owns 1,077,083 shares of the company's stock valued at $329,689,000 after purchasing an additional 843,348 shares in the last quarter. Artemis Investment Management LLP purchased a new position in McKesson during the second quarter valued at $109,168,000. 1832 Asset Management L.P. purchased a new position in McKesson during the first quarter valued at $99,472,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in McKesson by 53.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 915,949 shares of the company's stock valued at $280,399,000 after purchasing an additional 320,588 shares in the last quarter. 86.43% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Lori A. Schechter sold 2,500 shares of McKesson stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $347.13, for a total value of $867,825.00. Following the completion of the transaction, the executive vice president now owns 9,178 shares in the company, valued at $3,185,959.14. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Lori A. Schechter sold 7,500 shares of McKesson stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $343.94, for a total value of $2,579,550.00. Following the completion of the transaction, the executive vice president now owns 11,678 shares in the company, valued at $4,016,531.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Lori A. Schechter sold 2,500 shares of the business's stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $347.13, for a total value of $867,825.00. Following the transaction, the executive vice president now owns 9,178 shares of the company's stock, valued at approximately $3,185,959.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,300 shares of company stock worth $3,924,748. Corporate insiders own 0.21% of the company's stock.

Analyst Upgrades and Downgrades

McKesson Trading Up 1.8 %

Shares of MCK stock opened at $365.48 on Monday. McKesson Co. has a 12-month low of $202.61 and a 12-month high of $375.23. The stock's 50-day moving average price is $356.36 and its 200-day moving average price is $336.52. The stock has a market capitalization of $52.53 billion, a price-to-earnings ratio of 38.63, a price-to-earnings-growth ratio of 1.46 and a beta of 0.61.

McKesson (NYSE:MCK – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $5.83 EPS for the quarter, topping the consensus estimate of $5.31 by $0.52. The company had revenue of $67.15 billion during the quarter, compared to analyst estimates of $63.87 billion. McKesson had a negative return on equity of 350.22% and a net margin of 0.52%. As a group, research analysts predict that McKesson Co. will post 24.41 EPS for the current fiscal year.

McKesson Profile

(Get Rating)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.

See Also

• Get a free copy of the StockNews.com research report on McKesson (MCK)
• Time to Hit Up Hasbro Stock for the Holiday Season
• Should Proctor and Gamble be a Staple in Your Portfolio?
• 3 Fundamentally Sound Mid-Caps to Keep on the Watch List
• Leveraged ETFs, A Bad Investment But Great for Trading
• Should Investors Raise a Glass to Boston Beer Company?

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.